2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Monday, November 9, 2015

9:00AM-11:00AM: Abstract Number: 1569

Rituximab Efficacy in the Treatment of Diffuse Interstitial Lung Disease Associated with Rheumatoid Arthritis

Rheumatoid Arthritis - Clinical Aspects Poster II

9:00AM-11:00AM: Abstract Number: 1625

Role of Macrophages in the Cardiovascular Disease Associated to Rheumatoid Arthritis: Effects of ANTI-CCPS in the Phenotypic Switching and the Insulin Signalling

Rheumatoid Arthritis - Human Etiology and Pathogenesis Poster II

9:00AM-11:00AM: Abstract Number: 1118

Role of the Chemokine Receptor CXCR3 in the Function of Regulatory B Cells in Patients with SLE

B cell Biology and Targets in Rheumatolid Arthritis and other Autoimmune Disease Poster

9:00AM-11:00AM: Abstract Number: 1921

Role of TLRs in the Abnormal Secretion of CXCL-4 By Plasmacytoid Dendritic Cells of Patients with Systemic Sclerosis

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Pathogenesis, Animal Models and Genetics Poster I

9:00AM-11:00AM: Abstract Number: 1769

Role of Topical Administration of Peptidylarginine Deiminase Inhibitors in Murine Lupus

Systemic Lupus Erythematosus - Animal Models Poster II

9:00AM-11:00AM: Abstract Number: 1644

Routine Assessment of Patient Index Data 3 (RAPID3)-Defined Remission Is As Stringent As ACR/EULAR Boolean-Defined Remission in a Clinical Trial of Patients with Early Rheumatoid Arthritis Treated with Abatacept

Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster II

9:00AM-11:00AM: Abstract Number: 1417

Rural Residence Does Not Impact Total Ankle Arthroplasty Utilization and Outcomes

Orthopedics, Low Back Pain and Rehabilitation Poster

9:00AM-11:00AM: Abstract Number: 1375

S100A8/A9, a Serum and Imaging Biomarker for Assessing Joint Inflammation and Destruction in Experimental Seronegative Arthritis

Innate Immunity and Rheumatic Disease Poster II

9:00AM-11:00AM: Abstract Number: 1839

Safety and Immunogenicity of Quadrivalent Human Papilloma Virus (qHPV) Vaccine (Gardasil®) in Systemic Lupus Erythematous (SLE), Phase I Trial Completion

Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session II

9:00AM-11:00AM: Abstract Number: 1603

Safety of Biologic and Non-Biologic Disease-Modifying Antirheumatic Drug (DMARD) Therapy in Veterans with Rheumatoid Arthritis and Chronic Hepatitis C Infection

Rheumatoid Arthritis - Clinical Aspects Poster II

9:00AM-11:00AM: Abstract Number: 1520

Safety, Clinical and Immunologic Effectiveness of the Live Zoster Vaccine Administered to Patients Receiving Anti-TNF Biologics

Rheumatoid Arthritis - Clinical Aspects Poster II

9:00AM-11:00AM: Abstract Number: 1927

Salinomycin Induces Potent Suppression of TGF-β1-Mediated Expression of Profibrotic Genes in Cultured Dermal Fibroblasts from Normal Donors and from Donors with Systemic Sclerosis (SSc): A Novel Anti-Fibrotic Treatment for Tissue Fibrosis in SSc

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Pathogenesis, Animal Models and Genetics Poster I

9:00AM-11:00AM: Abstract Number: 1696

Score Classification Underestimates the Real Cardiovascular Risk in Psoriatic Arthritis Patients

Spondylarthropathies and Psoriatic Arthritis - Comorbidities and Treatment Poster II

9:00AM-11:00AM: Abstract Number: 1521

Screening for Urinary Tract Infection in Rheumatoid Arthritis Patients Treated with TNF-Inhibitors in the Daily Clinic

Rheumatoid Arthritis - Clinical Aspects Poster II

9:00AM-11:00AM: Abstract Number: 1680

Selective JAK1 Inhibition with Filgotinib (GLPG0634) Decreases Plasma Markers of Inflammation and Joint Damage in Patients with Rheumatoid Arthritis

Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].